Related Experiment Videos
Negative regulation of Janus kinases
R J Duhé1, L H Wang, W L Farrar
1Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson 39216-4505, USA. rduhe@pharmacology.umsmed.edu
Abstract:
The precise regulation of both the magnitude and the duration of Janus kinase (JAK) catalytic activity is essential for the cytokine orchestration of many biological processes, and the dysregulation of JAK activity has pathological implications. Immunosuppressive disease states, such as X-linked severe combined immunodeficiency, arise from inappropriate JAK inhibition. In contrast, a limited number of cancers, primarily leukemias, result from constitutive or enhanced activation of JAK activity. JAKs are no longer implicated only in classic cytokine receptor-mediated signaling pathways, but are now also known to integrate indirectly into other receptor-mediated signal transduction processes. Therefore, an increasing number of therapeutic applications exist for biological-response modifiers that can restore aberrant JAK activity to normal levels. Exciting breakthroughs in both physiological and pharmacological methods of selective inhibition of cytokine-JAK-signal transducers and activators of transcription pathways have recently emerged in the form of suppressors of cytokine signaling (also known as cytokine-inducible SH2 protein, JAK-binding protein, or STAT-induced STAT inhibitor) proteins and novel dimethoxyquinazoline derivatives, respectively. The basis of these and other mechanisms of negative regulation of JAK activity, including the suppression of jak expression levels caused by tumor- or pathogen-derived agents, the complex interactions of JAKs with phosphatases, and the redox regulation of JAK catalytic activity, is the focus of this review.
Insights
Precise Janus kinase (JAK) regulation is vital for biological processes. Dysregulated JAK activity, from inhibition to overactivation, causes diseases like immunodeficiency and leukemia, necessitating therapeutic interventions.
Area of Science:
- Molecular Biology
- Immunology
- Oncology
Background:
- Janus kinases (JAKs) are crucial for cytokine signaling, influencing numerous biological processes.
- Dysregulation of JAK activity is linked to pathological conditions, including immunosuppression (e.g., X-linked severe combined immunodeficiency) and cancers (e.g., leukemias).
- JAKs are increasingly recognized for their role beyond classic cytokine receptor pathways, integrating into other signaling cascades.
Purpose of the Study:
- To review the mechanisms of negative regulation of Janus kinase (JAK) activity.
- To highlight therapeutic strategies aimed at restoring aberrant JAK activity to normal levels.
- To discuss emerging physiological and pharmacological approaches for JAK pathway modulation.
Main Methods:
- Review of literature on JAK regulation and therapeutic interventions.
- Analysis of suppressors of cytokine signaling (SOCS) proteins as physiological inhibitors.
- Examination of novel pharmacological agents, such as dimethoxyquinazoline derivatives.
- Exploration of JAK interactions with phosphatases and redox regulation.
- Discussion of JAK expression suppression by endogenous or exogenous agents.
Main Results:
- JAK catalytic activity requires precise control of both magnitude and duration.
- Inappropriate JAK inhibition leads to immunosuppressive states, while enhanced JAK activity contributes to certain cancers.
- Novel therapeutic strategies, including protein-based inhibitors and small molecules, are emerging to modulate JAK activity.
- Negative regulation of JAKs involves complex mechanisms including SOCS, phosphatases, and redox control.
Conclusions:
- Restoring normal JAK activity is a key therapeutic goal for various diseases.
- Understanding the diverse mechanisms of JAK regulation is essential for developing effective treatments.
- Future research directions include further exploration of JAK interactions and the development of targeted therapies.